<PAGE>
As filed with the Securities and Exchange Commission on October 6, 2000
Registration No. 333-
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
--------------
FORM S-3
REGISTRATION STATEMENT
Under
THE SECURITIES ACT OF 1933
--------------
CURAGEN CORPORATION
(Exact name of registrant as specified in its charter)
--------------
Delaware 06-1331400
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification Number)
555 Long Wharf Drive, 11th Floor
New Haven, Connecticut 06511
(203) 401-3330
(Address, including zip code, and telephone number, including area code, of
registrant's principal executive offices)
--------------
JONATHAN M. ROTHBERG, Ph.D.
Chief Executive Officer, President and
Chairman of the Board
CuraGen Corporation
555 Long Wharf Drive, 11th Floor
New Haven, Connecticut 06511
(203) 401-3330
(Name, address, including zip code, and telephone number, including area code,
of agent for service)
With a copy to:
Michael L. Fantozzi, Esquire
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
One Financial Center
Boston, Massachusetts 02111
(617) 542-6000
--------------
Approximate date of commencement of proposed sale to the public: As soon
as practical after this Registration Statement becomes effective.
If the only securities being registered on this Form are being offered
pursuant to dividend or interest reinvestment plans, please check the
following box. [_]
If any of the securities being registered on this Form are to be offered on
a delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933 other than securities offered only in connection with dividend or
interest reinvestment, check the following box. [X]
If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, please check the following
box and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering. [_]
If delivery of the prospectus is expected to be made pursuant to Rule 434,
please check the following box. [_]
CALCULATION OF REGISTRATION FEE
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
<TABLE>
<CAPTION>
Proposed
Maximum
Aggregate Amount of
Title of each Class of Offering
Securities to be Registered(1) Price(2)(3) Registration Fee(4)
------------------------------------------------------------------------------------------------------
<S> <C> <C>
Common Stock, $0.01 par value per share(5)................... (6) (6)
------------------------------------------------------------------------------------------------------
Preferred Stock, $0.01 par value per share................... (6) (6)
------------------------------------------------------------------------------------------------------
Debt Securities ............................................. (6) (6)
------------------------------------------------------------------------------------------------------
Warrants..................................................... (6) (6)
------------------------------------------------------------------------------------------------------
Total........................................................ $500,000,000 $132,000
------------------------------------------------------------------------------------------------------
</TABLE>
-------------------------------------------------------------------------------
-------
(1) There are being registered hereunder such indeterminate number of shares
of common stock and preferred stock, such indeterminate number of warrants
to purchase common stock, preferred stock or debt securities, and such
indeterminate principal amount of debt securities as shall have an
aggregate initial offering price not to exceed $500,000,000. If any debt
securities are issued at an original issued discount, then the offering
price of such debt securities shall be in such greater principal amount as
shall result in an aggregate initial offering price not to exceed
$500,000,000, less the aggregate dollar amount of all securities
previously issued hereunder. Any securities registered hereunder may be
sold separately or as units with other securities registered hereunder.
The securities registered also include such indeterminate amounts and
numbers of common stock, preferred stock and debt securities as may be
issued upon conversion of or exchange for preferred stock or debt
securities that provide for conversion or exchange, upon exercise of
warrants or pursuant to the antidilution provisions of any such
securities.
(2) In United States dollars or the equivalent thereof in any other currency,
currency unit or units, or composite currency or currencies.
(3) The proposed maximum per unit and aggregate offering prices per class of
security will be determined from time to time by the registrant in
connection with the issuance by the registrant of the securities
registered hereunder.
(4) Estimated solely for purposes of determining the registration fee pursuant
to Rule 457(o) under the Securities Act of 1933, as amended.
(5) The aggregate amount of Common Stock registered hereunder is limited to
that which is permissible under Rule 415(a)(4) under the Securities Act.
(6) Not required to be included in accordance with General Instruction II.D.
of Form S-3.
--------------
The company hereby amends this Registration Statement on such date or dates
as may be necessary to delay its effective date until the company shall file a
further amendment which specifically states that this Registration Statement
shall thereafter become effective in accordance with Section 8(a) of the
Securities Act of 1933 or until the Registration Statement shall become
effective on such date as the Commission, acting pursuant to said Section
8(a), shall determine.
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
<PAGE>
++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
+The information in this prospectus is not complete and may be changed. We may +
+not sell these securities until the registration statement filed with the +
+Securities and Exchange Commission is effective. This prospectus is not an +
+offer to sell these securities and is not soliciting an offer to buy these +
+securities in any state where the offer or sale is not permitted. +
++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
Subject to Completion, dated October 6, 2000
PROSPECTUS
CURAGEN CORPORATION
$500,000,000
COMMON STOCK
PREFERRED STOCK
DEBT SECURITIES
WARRANTS
We may from time to time issue up to $500,000,000 aggregate principal amount
of common stock, preferred stock, debt securities and/or warrants. We will
specify in the accompanying prospectus supplement the terms of the securities.
We may sell these securities to or through underwriters and also to other
purchasers or through agents. We will set forth the names of any underwriters
or agents in the accompanying prospectus supplement.
-----------
INVESTING IN OUR SECURITIES INVOLVES RISKS.
SEE "RISK FACTORS" ON PAGE 4.
-----------
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES
COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE
ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS
A CRIMINAL OFFENSE.
This prospectus may not be used to consummate sales of securities unless it
is accompanied by a prospectus supplement.
The date of this prospectus is , 2000.
<PAGE>
TABLE OF CONTENTS
<TABLE>
<CAPTION>
Page
----
<S> <C>
ABOUT THIS PROSPECTUS...................................................... 2
OUR BUSINESS............................................................... 2
RISK FACTORS............................................................... 4
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS.......................... 15
USE OF PROCEEDS............................................................ 16
THE SECURITIES WE MAY OFFER................................................ 17
DESCRIPTION OF CAPITAL STOCK............................................... 17
DESCRIPTION OF DEBT SECURITIES............................................. 22
DESCRIPTION OF WARRANTS.................................................... 27
LEGAL OWNERSHIP OF SECURITIES.............................................. 29
PLAN OF DISTRIBUTION....................................................... 32
LEGAL MATTERS.............................................................. 33
EXPERTS.................................................................... 33
WHERE YOU CAN FIND MORE INFORMATION........................................ 33
INCORPORATION OF DOCUMENTS BY REFERENCE.................................... 33
</TABLE>
<PAGE>
ABOUT THIS PROSPECTUS
This prospectus is part of a registration statement that we filed with the
Securities and Exchange Commission, or SEC, utilizing a "shelf" registration
process. Under this shelf process, we may sell any combination of the
securities described in this prospectus in one or more offerings up to a total
dollar amount of $500,000,000. We have provided to you in this prospectus a
general description of the securities we may offer. Each time we sell
securities, we will provide a prospectus supplement that will contain specific
information about the terms of that offering.
OUR BUSINESS
The following is only a summary. We urge you to read the entire prospectus,
including the more detailed financial statements, notes to the financial
statements and other information incorporated by reference from our other
filings with the SEC. Investing in our common stock involves risk. Therefore,
carefully consider the information provided under the heading "Risk Factors"
beginning on page 4.
We are a genomics based drug discovery and development company. We develop
and use technologies to discover genes and to understand how they function in
order to accelerate the discovery and development of products to improve human
health, animal health and to improve agricultural vitality. We conduct this
work in collaboration with other pharmaceutical and biotechnology companies and
on our own behalf through internal discovery and development programs.
We make our technologies, processes and information systems accessible over
the Internet, fully integrate them with one another to improve efficiency and
ease of use, and rapidly generate comprehensive information about the
following:
. gene sequence; the order in which nucleotides (the building blocks of
DNA) appear in a gene and control the function of the gene;
. variations in gene sequences;
. gene expression (the degree of gene activity);
. biological pathways (the pathways that proteins follow in carrying out
the biological functions of cells); and
. the way potential drugs affect gene expression and the related biological
pathways.
Our base of technologies has three primary systems which consist of:
proprietary technologies, automated processes, and software used to analyze and
organize our biological databases. Each of our technologies is fully
operational and has been commercialized:
. SeqCalling(TM) which identifies sequences and discovers variations in
gene sequences known as Single Nucleotide Polymorphisms, or SNPs;
. GeneCalling(R), a patented technology that discovers genes and measures
gene activity; and
. PathCalling(R), a patented technology that analyzes the function and
relationships between genes and the proteins these genes encode in
biological pathways.
In addition to accelerating the discovery of new drug candidates, we use our
GeneCalling technologies, related biological databases, and software analysis
tools to predict the potential efficacy and safety of drug candidates currently
in pharmaceutical development pipelines, and to review the performance and side
effects of drugs already being marketed. This approach, referred to as
pharmacogenomics, is helping pharmaceutical companies develop more effective
and safer drugs.
2
<PAGE>
We have unified our SeqCalling, GeneCalling and PathCalling technologies,
processes and databases through a computer operating software program we refer
to as GeneScape. GeneScape enables users to access our technologies over the
Internet and provides researchers at multiple sites simultaneous, real-time
access to our technologies, systems and databases, allowing them to collaborate
on discovery and development projects. We plan to continue enhancing and
building additional technologies that we will incorporate into the GeneScape
operating software program.
We market our technologies and gene information to pharmaceutical,
biotechnology, agricultural and animal health companies through research
collaborations. These collaborations typically provide current revenues,
milestone payments for successful projects, and royalty-based revenues from our
partners' drug development programs. We have conducted research for Abgenix,
Inc., Biogen, Inc., COR Therapeutics, Inc., DuPont/Pioneer Hi-Bred
International, Inc., Gemini Genomics plc, Genentech, Inc., Glaxo-Wellcome,
Inc., Hoffmann-La Roche Inc. and its affiliate, Roche Vitamins, Inc. and Ono
Pharmaceuticals.
We also apply our suite of genomics technologies on our own behalf to build
a broad portfolio of research programs that encompass drug discovery, drug
development and pharmacogenomics. We have established internal programs to
discover products to treat metabolic diseases, cancer, autoimmune and
inflammatory diseases and disorders of the central nervous system. During the
next five years, our objective is to systematically analyze the genetic basis
of many common diseases, study how many commonly prescribed drugs work and
identify their potentially adverse side effects, while building a proprietary
pipeline of therapeutic products.
We focus our efforts on research programs that address unmet medical needs
and that we believe have the potential to yield products that can be
commercialized in a relatively short time. At each stage, we plan to reevaluate
the relative merits of continuing such programs solely through internal efforts
or through research collaborations.
The goal of our drug development programs is to advance promising
therapeutic candidates into the FDA's clinical approval process. We currently
focus on two broad classes of therapeutics: secreted proteins and fully human
antibodies. We are currently evaluating the efficacy of a number of secreted
proteins as potential human therapeutics using animal models. Antibodies are
naturally occurring proteins used by the body's immune system to combat many
diseases. As therapeutic products, antibodies have several potential advantages
over other therapies such as reducing unwanted side effects that may occur with
other therapies. Fully human antibodies are desirable because they avoid the
risk of rejection present with mouse or partial mouse antibodies.
We file patent applications to protect our genomics technologies, gene-
related discoveries, products, information systems and proprietary databases,
software and other methods and technology. As of October 3, 2000, we had
approximately 435 patent applications pending with the United States Patent and
Trademark Office, and had filed numerous corresponding international and
foreign patent applications. As of October 3, 2000, the U.S. Patent Office has
issued us 11 patents for aspects of our technologies, discoveries and products.
We incorporated in Delaware in November 1991. Our principal executive
offices are located at 555 Long Wharf Drive, 11th Floor, New Haven, Connecticut
06511. Our telephone number is (203) 401-3330. We maintain a web site on the
Internet at http://www.curagen.com. We do not intend for the information in our
web site to be considered part of this prospectus.
3
<PAGE>
RISK FACTORS
Investing in our common stock is very risky. You should carefully consider
the following risk factors and all other information contained in this
prospectus and incorporated by reference before purchasing our securities. You
should be able to bear a complete loss of your investment. See "Special Note
Regarding Forward-Looking Statements."
We have a history of operating losses and expect to incur losses in the future
and we may never achieve or maintain profitability.
We have a limited operating history and we have experienced operating losses
since our inception and expect these losses to continue for the next several
years. We may never be profitable or achieve significant revenues. For example,
we experienced net losses of $25,762,760 in 1999, $18,936,920 in 1998 and
$7,290,434 in 1997. In order to develop our technologies, including expanding
our SeqCalling, GeneCalling and PathCalling database development efforts, we
expect to incur significant increases in our expenses over the next several
years. In addition, we expect significant increases in expenses in connection
with our internal research and product development programs. As a result, we
expect to incur operating losses at least through 2002. Our ability to achieve
significant revenues and profitability will depend upon obtaining additional
research collaborations and subscribers for our SeqCalling, GeneCalling and
PathCalling products, services and related databases and our internal
development programs. We may not be able to obtain any additional research
collaborations or enter into any additional subscription arrangements for
products, services, databases or our internal development programs. As a
result, we may never achieve or maintain profitability.
Our technologies and products are at an early stage of development and may
never be commercially viable or successful.
Our technologies and databases are still in the early stages of development
and we have just begun to incorporate our technologies into commercialized
products. Our products focus primarily on the development of diagnostic drugs
to treat a variety of complex human and animal diseases and agronomic traits.
There is limited scientific understanding generally relating to the role of
genes in these diseases and traits, and few products based on gene discoveries
have been developed and commercialized. Accordingly, even if we were successful
in identifying genes, biological pathways or drug candidates associated with
specific diseases or in identifying genes associated with certain agronomic
traits, we or our collaborators may not be able to develop or commercialize
products to improve human and animal health and the vitality of agriculture.
In addition, our SeqCalling, GeneCalling and PathCalling products and
services and the related databases are in the early stage of development. These
products systematically analyze the genetic information contained within a cell
to discover and develop novel therapeutic, agricultural and diagnostic
products. Their success will depend upon our ability to use software tools to
generate data concerning the following:
. gene sequences;
. gene variations;
. the level of gene activity;
. biological pathways; and
. drug candidates.
In addition, because of the complexity of such data, we may not be able to
detect any design defects or software errors in our existing or future
technologies and databases.
4
<PAGE>
Even if we or our collaborators develop products for commercial use, we may
not be able to develop products that:
. meet applicable regulatory standards, in a timely manner or at all;
. successfully compete with other technologies and products;
. avoid infringing the proprietary rights of others;
. can be manufactured in sufficient quantities or at reasonable cost; or
. can be marketed successfully.
Due to the specialized nature of our products, there are a limited number of
pharmaceutical, biotechnology and agricultural companies that are potential
customers for our products and services. Additional reasons why there may not
be a great demand for our products and services include:
. our potential collaborators and subscribers may determine to conduct in-
house gene research;
. our competitors may offer similar services at competitive prices;
. we may not be able to service satisfactorily our collaborators and
subscribers;
. others may publicly disclose or patent the proprietary information
contained in our databases (including information related to gene
expression, biological pathways or drug candidates); and
. technological innovations may be discovered that are more advanced than
those used by and available to us.
If there is not sufficient demand for our products we may never generate
enough revenues to become or stay profitable.
We may need to raise additional funding which may not be available on terms
acceptable to us, or at all, harming our ability to implement our business
plan.
We anticipate that our existing capital resources are not sufficient to fund
our future operating plans and we will need to raise significant additional
capital. We established a substantial scientific infrastructure to develop our
technologies and to add information to our databases. We used substantial
amounts of cash to establish this infrastructure and expect our capital and
operating expenses to increase over the next several years as we expand this
infrastructure and our research and development activities. The amount of
additional capital which we expect we will need to raise will depend on many
factors, including:
. the progress of our research programs;
. the number and breadth of our research programs;
. our ability to attract subscribers to our products and services;
. the achievement of the milestones under certain of our existing
collaborations;
. our ability to establish and maintain additional collaborations;
. the progress of our collaborators;
. our activities relating to the commercialization rights we have retained
in our collaborations;
. the costs incurred in enforcing and defending our patent claims and other
intellectual property rights; and
. the costs and timing of obtaining regulatory approvals for any of our
products to improve human and animal health and the vitality of
agriculture.
5
<PAGE>
We expect to raise the additional capital we require through public or
private equity offerings, debt financings or additional collaborations and
licensing arrangements. Additional financing may not be available to us when we
need it, or, if available, we may not be able to obtain such financing on terms
favorable to us or our stockholders. If we raise additional capital by issuing
equity securities, your ownership in us will be diluted. If we raise additional
funds through collaborations and licensing arrangements, we may be required to
relinquish rights to certain of our technologies or product candidates, or to
grant licenses on unfavorable terms. If we relinquish rights or grant licenses
on unfavorable terms our revenues could decrease. If adequate funds are not
available on terms acceptable to us, or at all, our business, financial
condition and results of operations would be materially adversely affected.
We rely significantly on our collaborative partners, and if our partners reduce
or stop funding our research efforts or terminate their collaborations with us
entirely we may not be able to develop or commercialize our products.
We rely on collaborators for the preclinical study and clinical development
of therapeutics and for regulatory approval, manufacturing and marketing of
products resulting from the application of our technology. We also intend to
rely on certain collaborators for significant funding in support of our
research efforts. It is important, then, that we enter into research
collaborations and licensing arrangements with a variety of third parties so we
can implement our strategy to develop and commercialize products for the health
of humans and animals and the vitality of agriculture based upon our
discoveries.
Our agreements with collaborators typically allow them significant
discretion to elect whether to pursue such activities. We cannot control the
amount and timing of resources our collaborators devote to our programs or
potential products. In addition, our collaborators can terminate their
agreements with us any time the collaboration permits them to or if we
materially breach the contract. We may not be able to maintain or expand
existing collaborations or establish any additional research collaborations,
licensing or subscription arrangements. If any of our collaborators were to
breach or terminate its agreement with us or otherwise fail to conduct
collaborative activities successfully and in a timely manner, the preclinical
or clinical development or commercialization of product candidates or research
programs would be delayed or terminated. Moreover, if funding from one or more
of our collaborative programs were reduced or terminated, we would need to
devote additional internal resources to product development, scale back or
terminate certain research development programs or seek alternative
collaborators. Disputes may arise in the future with respect to the ownership
of rights to any technology developed with our collaborators. These and other
possible disagreements between collaborators and us could lead to delays in the
collaborative research, development or commercialization of certain
therapeutic, agricultural or diagnostic products, or could require or result in
litigation or arbitration to resolve. If our collaborative partners reduce or
stop funding our research efforts, or terminate their collaborations with us,
we may not be able to develop or commercialize our products. Such disputes
could materially adversely affect our business, financial condition and results
of operations.
We face intense competition which is likely to increase and could result in
reduced acceptance and demand for our technologies and products.
We face, and will continue to face, intense competition from one or more of
the following entities:
. pharmaceutical companies;
. biotechnology companies;
. diagnostic companies;
. academic and research institutions; and
. government agencies.
6
<PAGE>
We are also subject to significant competition from organizations that are
pursuing technologies and products that are the same as or similar to our
technology and products. Many of the organizations competing with us have
greater capital resources, research and development staffs and facilities and
marketing capabilities. In addition, research in the field of genomics
generally is highly competitive. Our competitors in the genomics area include:
. Human Genome Sciences, Inc.;
. Millennium Pharmaceuticals, Inc.;
. Myriad Genetics, Inc.
. major pharmaceutical companies; and
. universities and other research institutions (including those receiving
funding from the federally funded Human Genome Project).
We believe that our future success will depend in large part on our ability
to maintain a competitive position in the genomics field. Before we recover
development expenses for our products or technologies, such products or
technologies may become obsolete as a result of technological developments by
us or others. New technologies which are less expensive or more effective could
make our products obsolete. We may not be able to make the enhancements to our
technology necessary to compete successfully with newly emerging technologies.
A number of our competitors are attempting to rapidly identify and patent
genes and gene fragments sequenced at random, typically without specific
knowledge of the function of such genes or gene fragments. If our competitors
discover or characterize important genes or gene fragments before we do, it
could adversely affect any of our related disease research programs. We expect
that competition in genomics research will intensify as technical advances are
made and become more widely known. As a result, there may be reduced acceptance
and demand for our technologies and products.
If our patent applications do not result in issued patents, then our
competitors may obtain rights to commercialize our discoveries, which would
harm our competitive position.
Our business and competitive position depend upon our ability to protect our
SeqCalling, GeneCalling and PathCalling proprietary databases, proprietary
software and other proprietary methods and technology and related discoveries.
Our commercial success also depends in part on obtaining patent protection on
genes and proteins for which we or our collaborators or subscribers discover
utility and on products, methods and services based on such discoveries. We
have applied for patent protection on novel genes and proteins, novel mutants
of known genes and their uses, partial sequences of novel proteins and their
gene sequences and uses, and novel uses for previously identified genes
discovered by third parties. We also seek patent protection for our
therapeutic, diagnostic and drug screening methods and products. We have filed
patent applications for our proprietary methods and devices for gene expression
analysis, sequencing, discovery of biological pathways and for development. As
of October 3, 2000, we had approximately 435 patent applications pending
covering our technologies with the United States Patent and Trademark Office,
and had filed numerous corresponding international and foreign patent
applications. As of October 3, 2000, our patent applications have resulted in
11 issued patents with respect to aspects of our technology.
Patent law relating to the scope of claims in the technology fields in which
we operate is still evolving. The degree of future protection for our
proprietary rights is uncertain. Furthermore, third parties may independently
develop similar or alternative technologies, duplicate any of our technologies,
or, if patents are issued to us, design around the patented technologies
developed by us. We cannot predict whether our pending patent applications will
result in the issuance of valid patents. Litigation, which could result in
substantial cost to us, may be necessary to enforce our patent and proprietary
rights and/or to determine the scope and validity of others' proprietary
rights. We may participate in interference proceedings that may in the future
be declared
7
<PAGE>
by the United States Patent and Trademark Office to determine priority of
invention, which could result in substantial cost to us. The outcome of any
such litigation or interference proceeding might not be favorable to us. If our
patent applications do not result in issued patents, we may not be able to
compete effectively.
If the scope of our issued patents does not provide us with sufficient
protection of our intellectual property from our competitors we may not be able
to compete effectively.
The patent positions of pharmaceutical, biopharmaceutical and biotechnology
companies, including us, are uncertain and involve complex legal and factual
questions. The scope of our issued patents may not protect our technologies and
products because:
. our pending patent applications may not result in issued patents;
. additional proprietary technologies we develop, if any, may not be
patentable;
. patents issued to us or our collaborative customers may not provide a
basis for commercially viable products;
. patents issued to us or our collaborative customers may not provide us
with any competitive advantages;
. patents issued to us or our collaborative customers may be challenged or
circumvented or invalidated by third parties; and
. patents issued to others may have an adverse effect on our ability to do
business.
The public availability of expressed sequence tags, genomic sequence
information or other sequence information prior to the time we apply for patent
protection on a corresponding full-length or partial gene could adversely
affect our ability to obtain patent protection with respect to such gene or
gene sequences. We may not be able to obtain further patents for our products
or methods, or, if we are able to obtain further patents, these patents may not
provide us with substantial protection or be commercially beneficial. The
issuance of a patent is not conclusive as to its validity or enforceability,
nor does it provide the patent holder with freedom to operate without
infringing the patent rights of others. Third parties could initiate lawsuits
against us to challenge our patents and, if we lose, our competitors could be
free to use the subject matter covered by the patent, or we may license the
technology to others to settle such litigation. If a court invalidates key
patents that we own or license or the U.S. Patent Office does not approve our
pending patent applications we may not be able to compete effectively in the
marketplace.
If we infringe upon third parties' patents, those parties could sue us for
patent infringement or they could require us to pay licensing fees which could
increase our expenses.
Our competitors and other groups are attempting to rapidly identify and
characterize genes through the use of gene expression analysis and other
technologies. To the extent any patents issue to other parties on such partial
or full-length genes or uses for such genes, the risk increases that the sale
of potential products, including therapeutics, or processes developed by us or
our collaborators may give rise to claims of patent infringement. We have
sought and intend to continue seeking patent protection for novel uses for
genes and proteins which may have been patented by third parties. In such
cases, we would need a license from the holder of the patent with respect to
such gene or protein in order to make, use or sell such gene or protein for
such use. We may not be able to acquire such licenses on commercially
reasonable terms, if at all.
In addition, others may have filed and in the future are likely to file
patent applications covering genes or gene products that are similar or
identical to our products. Any such patent application may have priority over
our patent applications. Any legal action against us or our collaborators
claiming damages and seeking to enjoin commercial activities relating to the
affected products and processes could, in addition to subjecting us to
potential liability for damages, require us or our collaborators to obtain a
license in order to continue to manufacture or market the affected products and
processes or could enjoin us from continuing to manufacture or market the
affected products and processes. We or our collaborators might not prevail in
any such action or
8
<PAGE>
that any license required under any such patent would be made available on
commercially acceptable terms, if at all. We believe that there may be
significant litigation in the industry regarding patent and other intellectual
property rights. If we become involved in such litigation, it could consume a
substantial portion of our managerial and financial resources.
A third party has indicated to us that it believes at some time in the
future we may be required to obtain a license in order to perform certain
processes that we use in the conduct of our business. We believe that, if
required, such license would be available on commercially reasonable terms.
If our security measures do not protect our proprietary technologies, we may
not be able to protect our trade secrets harming our competitive position.
We rely upon trade secret protection for some of our confidential and
proprietary information that is not subject matter for which patent protection
is being sought. We believe that we have developed proprietary technology,
processes and information systems for use in gene expression, biological
pathway and molecular target discovery, including proprietary biological
protocols, instrumentation, robotics and automation, software and an integrated
bioinformatics system. In addition, we have developed databases of proprietary
gene expression patterns and sequencing, human genetic variations, biological
pathways and the effects of drugs on gene expression which we update on an
ongoing basis and which can be accessed over the Internet. We have taken
security measures to protect our proprietary technologies, processes,
information systems and data and continue to explore ways to enhance such
security. Such measures, however, may not provide adequate protection for our
trade secrets or other proprietary information. While we require employees,
academic collaborators and consultants to enter into confidentiality and/or
non- disclosure agreements where appropriate, any of the following could still
occur:
. third parties could disclose proprietary information about us;
. others may independently develop substantially equivalent proprietary
information and techniques or otherwise gain access to our trade secrets
or disclose such technology; or
. we may not be able to meaningfully protect our trade secrets.
If our competitors learn our trade secrets, we may not be able to compete
effectively in the market.
If we cannot retain commercialization rights for our technologies and products
we may not realize revenue from those technologies and products.
In our research collaborations, we seek to retain commercialization rights
for the development and marketing of certain products or services to improve
human and animal health and the vitality of agriculture. We may not be
successful in retaining such rights and we have not developed any
pharmaceutical, agricultural or diagnostic products or services to date. We may
seek to commercialize any future retained rights, as well as any products
developed in our internal development programs, directly or through
collaborations with others. The value of these rights and products, if any,
will be largely derived from our gene expression, biological pathway and drug
screening efforts, the success of which is also uncertain. Even if we identify
and label relevant disease-related genes, biological pathways and/or drug
candidates, we do not currently have sufficient infrastructure, including
manufacturing and marketing, to commercialize our retained rights. If we seek
to commercialize retained rights and products developed internally through
joint ventures or research collaborations, we may be required to relinquish
material rights on terms that may not be favorable to us. If we cannot retain
and develop commercialization rights for our technologies and products we may
not realize revenue from those technologies and products.
9
<PAGE>
If we, or our collaborators, do not comply with government regulations, we may
not be able to develop or sell our technologies and products.
Prior to the marketing of any new drug developed by us or our collaborative
customers, that new drug must undergo an extensive regulatory approval process
in the United States and other countries. This regulatory process includes
preclinical and clinical studies, as well as post-marketing surveillance to
establish a compound's safety and efficacy, and can take many years and require
substantial resources. Data obtained from such studies are susceptible to
varying interpretations that could delay, limit or prevent regulatory approval.
The rate of completion of clinical trials is dependent upon, among other
factors, the enrollment of patients. Patient accrual is a function of many
factors, including:
. the size of the patient population;
. the proximity of patients to clinical sites;
. the eligibility criteria for the study; and
. the existence of competitive clinical trials.
Delays in planned patient enrollment in clinical trials may result in
increased costs, program delays, or both. We may encounter delays or rejections
based upon changes in United States Food and Drug Administration policies for
drug approval during the period of product development and FDA regulatory
review of each submitted new drug application, in the case of new
pharmaceutical agents, or product license application in the case of biologics.
We may also encounter similar delays in the regulatory approval of any
diagnostic product and in obtaining regulatory approvals in foreign countries.
Under current guidelines, proposals to conduct clinical research involving gene
therapy at institutions supported by the National Institutes of Health must be
approved by the Recombinant DNA Advisory Committee and the National Institutes
of Health. Because some of the products that result from our disease research
programs involve new technologies and may be based upon a new therapeutic
approach, such products may be subject to substantial additional review by
various government regulatory authorities and, as a result, we may obtain
regulatory approvals more slowly than for products using more conventional
technologies.
Even if we obtain regulatory approval for and market a product, such product
and its manufacturer are subject to continuing review. We may be adversely
affected by the discovery of previously unknown problems with a product,
including withdrawal of the product from the market. We could incur various
adverse consequences as a result of any of the following events:
. violations of regulatory requirements at any stage, including preclinical
studies and clinical trials, the approval process or post- approval;
. the FDA's delay in approval or refusal to approve a product;
. withdrawal of an approved product from the market; or
. the imposition of criminal penalties against the manufacturer and new
drug application or product license application holder.
We have not submitted an investigational new drug application for any
product candidate of ours, and no product candidate has been approved for
commercialization in the United States or elsewhere. With respect to our
internal discovery and drug programs, we may rely on our collaborators to file
investigational new drug applications and generally direct the regulatory
approval process. We or any of our collaborators may not be able to conduct
clinical testing or obtain the necessary approvals from the FDA or other
regulatory authorities for any products. If we do not obtain required
governmental approvals we may delay or preclude our collaborators from
marketing drugs or diagnostic products developed by us or limit the commercial
use of such products.
10
<PAGE>
We use hazardous materials and chemicals in our business and any disputes
relating to improper handling, storage or disposal of these materials could be
time consuming and costly.
Our research and development activities involve the controlled use of
hazardous materials and chemicals. We are subject to federal, state and local
laws and regulations governing the use, storage, handling and disposal of such
materials and certain waste products. Although we believe that our safety
procedures for handling and disposing of such materials comply with the
standards prescribed by federal, state and local laws and regulations, the risk
of accidental contamination or injury from these materials cannot be completely
eliminated. In the event of such an accident, third parties could hold us
liable for any damages that result and any liability could exceed our
resources.
If we fail to retain our key personnel and hire, train and retrain qualified
employees, we may not be able to develop or commercialize our technologies.
We depend on the principal members of our management and scientific staff,
including Dr. Jonathan M. Rothberg, our Chief Executive Officer, President and
Chairman of the Board. We have not entered into employment agreements with any
of the principal members of our management or scientific staff that bind any of
them to a specific term of employment. We maintain key person life insurance on
the life of Dr. Rothberg in the amount of $2,000,000. Our future success also
will depend in part on the continued services of our key scientific and
management personnel and our ability to attract, hire and retain additional
personnel. There is intense competition for such qualified personnel and there
can be no assurance that we will be able to continue to attract and retain such
personnel. If we fail to retain our key personnel and hire, train and retrain
qualified employees, we may not be able to develop or commercialize our
technologies.
If we do not retain our current licensed technologies and acquire new ones, we
might not be able to pursue our research and development activities.
We have acquired or licensed certain components of our technologies from
third parties. If any third party changed or terminated their licensing
agreements with us, we may not be able to obtain the components we need to
develop our technologies In addition, some of our licenses impose an obligation
on us to market the licensed technology to third parties. If we breach any of
these licenses or fail to maintain rights to such technology we may not be able
to continue our research and development activities or begin new ones.
The government has certain rights to funded technologies and we may have to
provide some of our technology for free which could increase our expense
without a corresponding increase in revenue.
Under existing government grants and agreements, the government has a
statutory right to practice or have practiced and, under certain circumstances
(including inaction on our part or our licensees to achieve practical
application of the invention or a need to alleviate public health or safety
concerns not reasonably satisfied by us or our licensees), to grant to other
parties licenses under, any inventions first reduced to practice under the
government grants and agreements. If the government exercises its rights to
obtain our technologies for free we could experience an increase in expenses
without a corresponding increase in revenues.
If we fail to maintain our relationships with our academic collaborators and
scientific advisors, or acquire new relationships, we may not be able to
research or develop new technologies or products.
We have relationships with collaborators and consultants at academic and
other institutions who conduct research at our request. Such collaborators and
consultants are not our employees. Substantially all of our collaborators and
consultants are employed by employers other than us and may have commitments
to, or consulting or advisory contracts with, other entities that may limit
their availability to us. As a result, we have limited control over their
activities and, except as otherwise required by our collaboration and
consulting agreements, can expect only limited amounts of their time to be
dedicated to our activities. Our ability to discover genes and biological
pathways involved in human disease and commercialize products based on those
11
<PAGE>
discoveries may depend in part on continued collaborations with researchers at
academic and other institutions. We may not be able to negotiate additional
acceptable collaborations with collaborators or consultants at academic and
other institutions, which could hinder our ability to research and develop new
technologies and products.
Our academic collaborators, consultants and scientific advisors may have
relationships with other commercial entities, some of which could compete with
us. Our academic collaborators, consultants and scientific advisors sign
agreements which provide for confidentiality of our proprietary information and
of the results of studies. We may not be able to maintain the confidentiality
of our technology and other confidential information in connection with every
academic collaboration or advisory arrangement, and any unauthorized
dissemination of our confidential information could harm our competitive
position.
We have a lengthy sales cycle for our technologies and products that can
increase our expenses without a corresponding increase in revenue.
Our ability to obtain collaborators and subscribers for our products and
services depends in significant part upon the perception that such products and
services can help accelerate drug discovery and development efforts. Our sales
cycle is typically lengthy because we must educate our customers about our
products and sell the benefits of our products and services to a variety of
constituencies within potential collaborators and subscribers, including
research and development personnel and key management. In addition, each
subscription and collaboration involves the negotiation of agreements
containing terms that may be unique to each subscriber or collaborator. If we
decide to seek collaborators to assist us in our discovery and development
programs, the education, sales and negotiation efforts related to any such
collaborations may lengthen the sales cycle of our products. We may expend
substantial funds and management effort without generating a database
subscription or a collaboration. As a result, we would increase our expenses
without a corresponding increase in revenues.
We anticipate that our quarterly operating results will fluctuate which could
have an adverse effect on our stock price.
Our results of operations historically have fluctuated on a quarterly basis
and can be expected to continue to fluctuate. In fiscal year 2000 our net loss
per common share was $0.14 for the three month period ending on March 31, 2000
and $0.30 for the six month period ending on June 30, 2000. We expect that
losses will continue to fluctuate from quarter to quarter and that such
fluctuations may be substantial. Quarterly operating results can fluctuate as a
result of a number of factors, including the following:
. the level of investment in our discovery and development programs and
related databases;
. the commencement, delay, cancellation or completion of contracts;
. the timing of option, license and milestone payments under our
agreements;
. the mix of services provided by us;
. the timing of start-up expenses for new services and facilities; and
. the timing and integration of acquisitions and changes in regulations
related to our products and services.
We believe that quarterly comparisons of our financial results are not
necessarily meaningful and you should not rely on them as an indication of our
future performance. In addition, fluctuations in quarterly results could
adversely affect the market price of our common stock in a manner unrelated to
our long-term operating performance.
12
<PAGE>
If we produce our own pharmaceutical products in the future, we may not have
the resources to bring them to market.
Although we are not in clinical trials with our own pharmaceutical products,
any products we develop in the future will require significant research and
development and preclinical testing, and will require extensive clinical
testing prior to submission of any regulatory application for commercial use.
If we undertake these activities without the collaboration of others, we may
need to expend significant funds. Such potential pharmaceutical products will
be subject to the risks of failure inherent in the development of
pharmaceutical products based on new technologies. These risks include the
possibility that:
. the products will be unsafe or ineffective or otherwise fail to receive
necessary regulatory clearances;
. the products, if safe and effective, will be difficult to manufacture on
a large scale or be uneconomical to market;
. proprietary rights of third parties will preclude us or our partners from
marketing such products; or
. third parties will market superior or equivalent products.
As a result, we may not be able to develop any commercially viable products.
Clinical trials or marketing of any such potential pharmaceutical products may
expose us to liability claims from the use of such pharmaceutical products. We
may not be able to obtain product liability insurance or maintain sufficient
coverage at a reasonable cost. In addition, should we choose to develop
pharmaceutical products internally, we will have to make significant
investments in pharmaceutical product development, marketing, sales and
regulatory compliance resources, and we will have to establish or contract for
the manufacture of products under the Good Manufacturing Practices of the FDA.
We may not have the resources to develop or commercialize successfully any
potential pharmaceutical products.
The uncertainty associated with pharmaceutical pricing, reimbursement and
related matters may adversely affect our business.
The continuing efforts of government and third party payors to contain or
reduce the costs of health care through various means may materially adversely
affect our business, financial condition and results of operations. In certain
foreign markets, pricing and profitability of prescription pharmaceuticals are
subject to government control. In the United States, we expect that there will
continue to be a number of federal and state proposals to implement similar
government control. In addition, increasing emphasis on managed care in the
United States will continue to put pressure on the pricing of pharmaceutical
and diagnostic products. Cost control initiatives could decrease the price that
we or any of our subscribers and collaborators receive for any products in the
future and may have a material adverse effect on our revenues and results of
operations. Further, to the extent that cost control initiatives have a
material adverse effect on our subscribers or collaborators, our ability to
commercialize our products and to realize royalties could be adversely
affected.
Our ability and the ability of any of our subscribers or collaborative
customers to commercialize pharmaceutical or diagnostic products may depend in
part on the extent to which reimbursement for the products will be available
from government and health administration authorities, private health insurers
and other third party payors. Significant uncertainty exists as to the
reimbursement status of newly approved health care products. Third party
payors, including Medicare, increasingly are challenging the prices charged for
medical products and services. Government and other third party payors are
increasingly attempting to contain health care costs by limiting both coverage
and the level of reimbursement for new pharmaceutical or diagnostic products
and by refusing in some cases to provide coverage for uses of approved products
for disease indications for which the FDA has not granted labeling approval.
Third party insurance coverage might not be available to patients for any
products discovered and developed by us or our subscribers or collaborators. If
adequate coverage and reimbursement levels are not provided by government and
other third party payors for our products, the market acceptance of these
products may be reduced. Any such reduction may have a material adverse effect
on our business, financial condition, results of operations and cash flows.
13
<PAGE>
Our stock price has been and may continue to be volatile and you could lose all
or part of your investment.
The market price of our common stock since our initial public offering in
March 1998 has been volatile. This volatility has been caused, and will in the
future continue to be caused by the following factors, some of which are beyond
our control:
. announcements of our results of research activities;
. our own publications;
. quarterly variations in our operating results;
. new collaborative agreements;
. technological innovations by ourselves and our competitors;
. announcements of new commercial products and initiatives by us,
collaborative partners or competitors;
. changes in government regulation or new regulatory actions;
. changes in patent laws;
. developments concerning proprietary rights;
. developments in litigation initiated by or against us; and
. fluctuations in the stock market price and volume of traded shares
generally, especially fluctuations in the traditionally volatile
technology and biotechnology sectors.
Our stock price could drop below the price you paid for your shares. As a
result, you could lose all or part of your investment.
We must sell a substantial number of additional shares of common stock, which
could adversely affect the trading price of our common stock.
We have a substantial number of shares of common stock subject to stock
options and warrants. We cannot predict the effect, if any, that future sales
of shares of common stock, or the availability of shares of common stock for
future sale, will have on the market price of our common stock. Sales of
substantial amounts of common stock (including shares issued upon the exercise
of stock options or warrants), or the perception that such sales could occur,
may adversely affect prevailing market prices for our common stock.
14
<PAGE>
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus and the documents incorporated by reference herein contain
forward-looking statements within the meaning of Section 27A of the Securities
Act and Section 21E of the Exchange Act. These statements relate to future
events or our future financial performance. These statements include but are
not limited to statements regarding (i) our plan to build additional
technologies and to enhance our GeneScape platform and to systematically
analyze the genetic basis of many common diseases, (ii) the expected
transformation of the pharmaceutical industry and our opportunity with respect
thereto, (iii) the likely success of our technologies, (iv) the expected
benefits of the linkage to be provided by our PathCalling systems, (v) the
expected benefits, effects, efficiency and performance of our services and
products, (vi) our ability (a) to overcome the limitations of competing
technologies, processes and databases by condensing key steps in gene-based
discovery and development, (b) to develop, through our products and services,
the next generation of therapeutic products for important complex diseases, (c)
to populate our databases, and (d) to develop, in a timely fashion, a broad
portfolio of research programs that encompass drug discovery, drug development
and pharmacogenomics, (vii) the capacity of our products to predict the
efficiency and safety of drugs already on the market, (viii) the suitability of
CuraGen discovered genes and proteins involved in diabetes, hypertension and
ischemic stroke as targets for small molecule drug development and (ix) the
expected future levels of losses, operating expenses and material commitments.
In some cases, you can identify forward-looking statements by terminology such
as "may," "will," "should," "expects," "anticipates," "believes," "estimates,"
"predicts," "potential" or "continue" or the negative of such terms or other
comparable terminology. These statements are only predictions and involve known
and unknown risks, uncertainties and other factors, including the risks
outlined under "Risk Factors" that may cause our or our industry's actual
results, levels of activity, performance or achievements expressed or implied
by such forward-looking statements. Before deciding to purchase our common
stock you should carefully consider the risks described in the "Risk Factors"
section, in additional to the other information set forth in this prospectus
and the documents incorporated by reference herein.
Although we believe that the expectations reflected in the forward-looking
statements are reasonable, we cannot guarantee future results, levels of
activity, performance or achievements. Moreover, neither we nor any other
person assumes responsibility for the accuracy and completeness of such
statements. We do not intend to update any of the forward-looking statements
after the date of this prospectus to conform such statement to actual results
except as required by law.
15
<PAGE>
USE OF PROCEEDS
We intend to use the net proceeds from this offering for general corporate
purposes, including our internal discovery and development programs and the
development of new technologies, general working capital and possible future
acquisitions.
We have not determined the amounts we plan to spend on any of the areas
listed above or the timing of these expenditures. As a result, our management
will have broad discretion to allocate the net proceeds from this offering.
Pending application of the net proceeds as described above, we intend to invest
the net proceeds of the offering in short-term, investment-grade, interest-
bearing securities.
16
<PAGE>
THE SECURITIES WE MAY OFFER
The descriptions of the securities contained in this prospectus, together
with the applicable prospectus supplements, summarize all the material terms
and provisions of the various types of securities that we may offer. We will
describe in the applicable prospectus supplement relating to any securities the
particular terms of the securities offered by that prospectus supplement. If we
indicate in the applicable prospectus supplement, the terms of the securities
may differ from the terms we have summarized below. We will also include in the
prospectus supplement information, where applicable, about material United
States federal income tax considerations relating to the securities, and the
securities exchange, if any, on which the securities will be listed.
DESCRIPTION OF CAPITAL STOCK
The following description of our capital stock and certain provisions of our
certificate of incorporation and bylaws is a summary and are qualified in its
entirety by the provisions of our certificate of incorporation and bylaws.
Our authorized capital stock consists of 250,000,000 shares of common stock,
par value of $.01 per share, 3,000,000 shares of non-voting common stock, par
value of $.01 per share and 5,000,000 shares of preferred stock, par value of
$.01 per share.
Common Stock
Holders of our common stock are entitled to one vote for each share held of
record on all matters submitted to a vote of the stockholders. The holders of
our common stock are entitled to receive ratably such dividends as are declared
by the Board of Directors out of funds legally available therefore except that
(a) no cash dividends will be declared and paid on the common stock unless at
the same time an equal cash dividend is declared and paid, per share, on the
non-voting common stock, and (b) no dividend of property (including our capital
stock) will be declared and paid on the common stock unless a dividend of an
equal amount of the same property has also been declared and paid, per share,
on the non-voting common stock. We have never declared or paid any cash
dividends on our capital stock. In the event we liquidate, dissolve or wind up
the affairs of our business, holders of common stock and non-voting common
stock have the right (together as one class) to a ratable portion of assets
remaining after the payment of all debts and other liabilities. Holders of our
common stock have neither preemptive rights nor rights to convert their common
stock into any other securities and are not subject to future calls or
assessments. There are no redemption or sinking fund provisions applicable to
the common stock. All outstanding shares of common stock are, and the shares
issuable upon conversion of the securities will be, fully paid and non-
assessable. The rights, preferences and privileges of the holders of common
stock are subject to, and may be adversely affected by, the rights of the
holders of our shares of preferred stock that we may designate and issue in the
future.
Non-Voting Common Stock
Except as provided under the Delaware General Corporate Law, the holder of
our non-voting common stock are not entitled to vote on any matters submitted
to a vote of stockholder. The holder of our non-voting common stock are
entitled to receive ratably such dividends as are declared by the Board of
Directors out of funds legally available therefore, except that (a) no cash
dividends will be declared and paid on our non-voting common stock unless at
the same time an equal cash dividend is declared and paid, per share, on our
common stock, and (b) no dividend of property (including capital stock) will be
declared and paid on our non-voting
17
<PAGE>
common stock unless a dividend of an equal amount of the same property has also
been declared and paid, per share, on our common stock. We have never declared
or paid any cash dividends on our capital stock. In the event we liquidate,
dissolve or wind up the affairs of our business, holder of our non-voting
common stock and common stock have the right (together as one class) to a
ratable portion of assets remaining after the payment of all debts and other
liabilities. Holder of our non-voting common stock have the right, at any time,
to convert each share of non-voting common stock into shares of common stock at
the rate of one share of common stock for each share of non-voting common
stock. In addition, upon the transfer of beneficial ownership of any shares of
non-voting common stock, those shares will be automatically converted into
shares of common stock at the rate of one share of common stock for each share
of non-voting common stock. This automatic conversion will not apply if that
transfer is made to (1) a majority-owned subsidiary of Genentech, (2) a
corporation of which Genentech is a wholly-owned subsidiary ("Genentech
Parent"), or (3) a wholly owned subsidiary of the Genentech Parent; except that
if that transfer is made to a wholly-owned subsidiary of Genentech or the
Genentech Parent and that wholly-owned subsidiary ceases to be a wholly-owned
subsidiary of Genentech or the Genentech Parent, then those shares will be
automatically converted into shares of our common stock at the rate of one
share of common stock for each share of non-voting common stock. Holder of our
non-voting common stock do not have preemptive rights and are not subject to
future calls or assessments. There are no redemption or sinking fund provisions
applicable to our non-voting common stock. The rights, preferences and
privileges of the holder of our non-voting common stock are subject to, and may
be adversely affected by, the rights of the holders of shares of preferred
stock that we may designate and issue in the future.
Preferred Stock
Our charter authorizes our board of directors to issue preferred stock in
one or more series and to determine the voting rights, dividend rights,
liquidation preferences, conversion rights, redemption rights, including
sinking fund provisions and redemption prices, and other terms and rights of
each series of preferred stock. We will fix the rights, preferences, privileges
and restrictions of the preferred stock of each series in the certificate of
designation relating to that series. We will incorporate by reference as an
exhibit to the registration statement which includes this prospectus the form
of any certificate of designation which describes the terms of the series of
preferred stock we are offering before the issuance of the related series of
preferred stock. This description will include:
. the title and stated value;
. the number of shares we are offering;
. the liquidation preference per share;
. the purchase price;
. the dividend rate, period and payment date, and method of calculation for
dividends;
. whether dividends will be cumulative or non-cumulative and, if
cumulative, the date from which dividends will accumulate;
. the procedures for any auction and remarketing, if any;
. the provisions for a sinking fund, if any;
. the provisions for redemption or repurchase, if applicable, and any
restrictions on our ability to exercise those redemption and repurchase
rights;
. any listing of the preferred stock on any securities exchange or market;
. whether the preferred stock will be convertible into our common stock,
and, if applicable, the conversion price, or how it will be calculated,
and the conversion period;
. whether the preferred stock will be exchangeable into debt securities,
and, if applicable, the exchange price, or how it will be calculated, and
the exchange period;
18
<PAGE>
. voting rights, if any, of the preferred stock;
. preemption rights, if any;
. restrictions on transfer, sale or other assignment, if any;
. whether interests in the preferred stock will be represented by
depositary shares;
. a discussion of any material or special United States federal income tax
considerations applicable to the preferred stock;
. the relative ranking and preferences of the preferred stock as to
dividend rights and rights if we liquidate, dissolve or wind up our
affairs;
. any limitations on issuance of any class or series of preferred stock
ranking senior to or on a parity with the series of preferred stock as to
dividend rights and rights if we liquidate, dissolve or wind up our
affairs; and
. any other specific terms, preferences, rights or limitations of, or
restrictions on, the preferred stock.
When we issue share of preferred stock under this prospectus, the shares
will fully be paid and nonassessable and will not have, or be subject to, any
preemptive or similar rights.
The General Corporation Law of Delaware provides that the holders of
preferred stock will have the right to vote separately as a class on any
proposal involving fundamental changes in the rights of holders of that
preferred stock. This right is in addition to any voting rights that may be
provided for in the applicable certificate of designation.
The preferred stock could have other rights, including economic rights
senior to our common stock, so that the issuance of the preferred stock could
adversely affect the market value of our common stock. The issuance of the
preferred stock may also have the effect of delaying, deferring or preventing a
change in control of us without any action by the stockholders.
Registration Rights
One of our stockholders has registration rights. After December 8, 2000,
Abgenix will have demand and piggyback registration rights with respect to
837,990 shares of common stock. Demand registration rights entitle the holder
to cause us to register its shares of common stock. Piggyback registration
rights allow the holder to include its shares of common stock in registration
statements that we file.
In connection with the exercise of registration demands by certain of our
stockholders, we have filed with the SEC two registration statements on Form S-
3, which were declared effective on March 8, 2000 and June 30, 2000,
respectively. These registration statements registered in the aggregate
8,242,856 shares of common stock, consisting of 1,955,272 shares of common
stock which we will issue to Genentech upon Genentech's conversion of that same
number of shares of non-voting common stock held by Genentech, 1,500,000 shares
held by Pequot Partners Fund, L.P., 1,500,000 shares held by Pequot
International Fund, Inc., 2,350,084 shares issuable upon conversion of our 6%
Convertible Subordinated Debentures due 2007, and 937,500 shares of common
stock which we will issue to holders of our warrants upon their exercise of
those warrants.
19
<PAGE>
Anti-Takeover Effects of Provisions of Our Charter and Bylaws
Our certificate of incorporation provides for our board of directors to be
divided into three classes, with staggered three-year terms. As a result, only
one class of directors will be elected at each annual meeting of stockholders,
with the other classes continuing for the remainder of their respective three-
year terms. Stockholders have no cumulative voting rights, and the stockholders
representing a majority of the shares of common stock outstanding are able to
elect all of the directors.
The stockholders may amend our bylaws or adopt new bylaws, only by the
affirmative vote of 66 2/3% the outstanding voting securities. A special
meeting of the stockholders may be called by the affirmative vote of a majority
of our Board of Directors. These provisions may have the effect of delaying,
deferring or preventing a change in control.
The classification of our board of directors and lack of cumulative voting
will make it more difficult for our existing stockholders to replace our board
of directors as well as for another party to obtain control of us by replacing
our board of directors. Since our board of directors has the power to retain
and discharge our officers, these provisions could also make it more difficult
for existing stockholders or another party to effect a change in management.
These and other provisions may have the effect of deterring hostile
takeovers or delaying changes in control or management. These provisions are
intended to enhance the likelihood of continued stability in the composition of
our board of directors and in the policies of our board of directors and to
discourage certain types of transactions that may involve an actual or
threatened change in control. These provisions are designed to reduce our
vulnerability to an unsolicited acquisition proposal. The provisions also are
intended to discourage certain tactics that may be used in proxy rights.
However, such provisions could have the effect of discouraging others from
making tender offers for our shares and, as a consequence, they also may
inhibit fluctuations in the market price of the our shares that could result
from actual or rumored takeover attempts. Such provisions also may have the
effect of preventing changes in our management.
Section 203 of the Delaware General Corporation Law
We are subject to Section 203 of the Delaware General Corporation Law,
which, subject to certain exceptions, prohibits a Delaware corporation from
engaging in any business combination with any interested stockholder for a
period of three years following the time that such stockholder became an
interested stockholder, unless:
. prior to such time, the board of directors of the corporation approved
either the business combination or the transaction that resulted in the
stockholder becoming an interested holder;
. upon consummation of the transaction that resulted in the stockholder
becoming an interested stockholder, the interested stockholder owned at
least 85% of the voting stock of the corporation outstanding at the time
the transaction commenced, excluding for purposes of determining the
number of shares outstanding those shares owned (a) by persons who are
directors and also officers and (b) by employee stock plans in which
employee participants do not have the right to determine confidentially
whether shares held subject to the plan will be tendered in a tender or
exchange offer; or
. at or subsequent to such time, the business combination is approved by
the board of directors and authorized at an annual or special meeting of
stockholders, and not by written consent, by the affirmative vote of at
least 66 2/3% of the outstanding voting stock which is not owned by the
interested stockholder.
In general, Section 203 defines "business combination" to include the
following:
. any merger or consolidation involving the corporation and the interested
stockholder;
. any sale, transfer, pledge or other disposition of 10% or more of the
assets of the corporation involving the interested stockholder;
20
<PAGE>
. subject to certain exceptions, any transaction that results in the
issuance or transfer by the corporation of any stock of the corporation
to the interested stockholder;
. any transaction involving the corporation that has the effect of
increasing the proportionate share of the stock or any class or series of
the corporation beneficially owned by the interested stockholder; or
. the receipt by the interested stockholder of the benefit of any loans,
advances, guarantees, pledges or other financial benefits by or through
the corporation.
In general, Section 203 defines "interested stockholder" as an entity or
person beneficially owning 15% or more of the outstanding voting stock of the
corporation and any entity or person affiliated with or controlling or
controlled by such entity or person.
Transfer Agent and Registrar
American Stock Transfer & Trust Company is the transfer agent and registrar
for our common stock.
21
<PAGE>
DESCRIPTION OF DEBT SECURITIES
The following description, together with the additional information we
include in any applicable prospectus supplements, summarizes the material terms
and provisions of the debt securities that we may offer under this prospectus.
While the terms we have summarized below will apply generally to any future
debt securities we may offer, we will describe the particular terms of any debt
securities that we may offer in more detail in the applicable prospectus
supplement. If we indicate in a prospectus supplement, the terms of any debt
securities we offer under that prospectus supplement may differ from the terms
we describe below.
We will issue the senior notes under the senior indenture which we will
enter into with a trustee to be named in the senior indenture. We will issue
the subordinated notes under the subordinated indenture which we will enter
into with a trustee to be named in the subordinated indenture. We have filed
forms of these documents as exhibits to the registration statement which
includes this prospectus. We use the term "indentures" to refer to both the
senior indenture and the subordinated indenture. The indentures will be
qualified under the Trust Indenture Act. We use the term "debenture trustee" to
refer to either the senior trustee or the subordinated trustee, as applicable.
The following summaries of material provisions of the senior notes, the
subordinated notes and the indentures are subject to, and qualified in their
entirety by reference to, all the provisions of the indenture applicable to a
particular series of debt securities. Except as we may otherwise indicate, the
terms of the senior indenture and the subordinated indenture are identical.
We conduct some of our operations through our subsidiaries. Our rights and
the rights of our creditors, including holders of debt securities, to the
assets of any subsidiary of ours upon that subsidiary's liquidation or
reorganization or otherwise would be subject to the prior claims of that
subsidiary's creditors, except to the extent that we may be a creditor with
recognized claims against the subsidiary. Our subsidiaries' creditors would
include trade creditors, debt holders, secured creditors and taxing
authorities. Except as we may provide in a prospectus supplement, neither the
debt securities nor the indentures restrict us or any of our subsidiaries from
incurring indebtedness.
General
We will describe in each prospectus supplement the following terms relating
to a series of notes:
. the title;
. any limit on the amount that may be issued;
. whether or not we will issue the series of notes in global form, the
terms and who the depository will be;
. the maturity date;
. the annual interest rate, which may be fixed or variable, or the method
for determining the rate and the date interest will begin to accrue, the
dates interest will be payable and the regular record dates for interest
payment dates or the method for determining such dates;
. whether or not the notes will be secured or unsecured, and the terms of
any secured debt;
. the terms of the subordination of any series of subordinated debt;
. the place where payments will be payable;
. our right, if any, to defer payment of interest and the maximum length of
any such deferral period;
. the date, if any, after which, and the price at which, we may, at our
option, redeem the series of notes pursuant to any optional redemption
provisions;
22
<PAGE>
. the date, if any, on which, and the price at which we are obligated,
pursuant to any mandatory sinking fund provisions or otherwise, to
redeem, or at the holder's option to purchase, the series of notes;
. whether the indenture will restrict our ability to pay dividends, or will
require us to maintain any asset ratios or reserves;
. whether we will be restricted from incurring any additional indebtedness;
. a discussion on any material or special United States federal income tax
considerations applicable to the notes;
. the denominations in which we will issue the series of notes, if other
than denominations of $1,000 and any integral multiple thereof; and
. any other specific terms, preferences, rights or limitations of, or
restrictions on, the debt securities.
Conversion or Exchange Rights
We will set forth in the prospectus supplement the terms on which a series
of notes may be convertible into or exchangeable for common stock or other
securities of ours. We will include provisions as to whether conversion or
exchange is mandatory, at the option of the holder or at our option. We may
include provisions pursuant to which the number of shares of common stock or
other securities of ours that the holders of the series of notes receive would
be subject to adjustment.
Consolidation, Merger or Sale
The indentures do not contain any covenant which restricts our ability to
merge or consolidate, or sell, convey, transfer or otherwise dispose of all or
substantially all of our assets. However, any successor to or acquirer of such
assets must assume all of our obligations under the indentures or the notes, as
appropriate.
Events of Default Under the Indenture
The following are events of default under the indentures with respect to any
series of notes that we may issue:
. if we fail to pay interest when due and our failure continues for 90 days
and the time for payment has not been extended or deferred;
. if we fail to pay the principal, or premium, if any, when due and the
time for payment has not been extended or delayed;
. if we fail to observe or perform any other covenant contained in the
notes or the indentures, other than a covenant specifically relating to
another series of notes, and our failure continues for 90 days after we
receive notice from the debenture trustee or holders of at least 25% in
aggregate principal amount of the outstanding notes of the applicable
series; and
. if specified events of bankruptcy, insolvency or reorganization occur as
to us.
If an event of default with respect to notes of any series occurs and is
continuing, the debenture trustee or the holders of at least 25% in aggregate
principal amount of the outstanding notes of that series, by notice to us in
writing, and to the debenture trustee if notice is given by such holders, may
declare the unpaid principal of, premium, if any, and accrued interest, if any,
due and payable immediately.
The holders of a majority in principal amount of the outstanding notes of an
affected series may waive any default or event of default with respect to the
series and its consequences, except defaults or events of default regarding
payment of principal, premium, if any, or interest, unless we have cured the
default or event of default in accordance with the indenture. Any waiver shall
cure the default or event of default.
23
<PAGE>
Subject to the terms of the indentures, if an event of default under an
indenture shall occur and be continuing, the debenture trustee will be under no
obligation to exercise any of its rights or powers under such indenture at the
request or direction of any of the holders of the applicable series of notes,
unless such holders have offered the debenture trustee reasonable indemnity.
The holders of a majority in principal amount of the outstanding notes of any
series will have the right to direct the time, method and place of conducting
any proceeding for any remedy available to the debenture trustee, or exercising
any trust or power conferred on the debenture trustee, with respect to the
notes of that series, provided that:
. the direction so given by the holder is not in conflict with any law or
the applicable indenture; and
. subject to its duties under the Trust Indenture Act, the debenture
trustee need not take any action that might involve it in personal
liability or might be unduly prejudicial to the holders not involved in
the proceeding.
. A holder of the notes of any series will only have the right to institute
a proceeding under the indentures or to appoint a receiver or trustee, or
to seek other remedies if:
. the holder has given written notice to the debenture trustee of a
continuing event of default with respect to that series;
. the holders of at least 25% in aggregate principal amount of the
outstanding notes of that series have made written request, and such
holders have offered reasonable indemnity to the debenture trustee to
institute the proceeding as trustee; and
. the debenture trustee does not institute the proceeding, and does not
receive from the holders of a majority in aggregate principal amount of
the outstanding notes of that series other conflicting directions within
60 days after the notice, request and offer.
These limitations do not apply to a suit instituted by a holder of notes if
we default in the payment of the principal, premium, if any, or interest on,
the notes.
We will periodically file statements with the debenture trustee regarding
our compliance with specified covenants in the indentures.
Modification of Indenture; Waiver
We and the debenture trustee may change an indenture without the consent of
any holders with respect to specific matters, including:
. to fix any ambiguity, defect or inconsistency in the indenture; and
. to change anything that does not materially adversely affect the
interests of any holder of notes of any series.
In addition, under the indentures, the rights of holders of a series of
notes may be changed by us and the debenture trustee with the written consent
of the holders of at least a majority in aggregate principal amount of the
outstanding notes of each series that is affected. However, we and the
debenture trustee may only make the following changes with the consent of each
holder of any outstanding notes affected:
. extending the fixed maturity of the series of notes;
. reducing the principal amount, reducing the rate of or extending the time
of payment of interest, or any premium payable upon the redemption of any
notes; or
. reducing the percentage of notes, the holders of which are required to
consent to any amendment.
24
<PAGE>
Discharge
Each indenture provides that we can elect to be discharged from our
obligations with respect to one or more series of debt securities, except for
obligations to:
. register the transfer or exchange of debt securities of the series;
. replace stolen, lost or mutilated debt securities of the series;
. maintain paying agencies;
. hold monies for payment in trust;
. compensate and indemnify the trustee; and
. appoint any successor trustee.
In order to exercise our rights to be discharged, we must deposit with the
trustee money or government obligations sufficient to pay all the principal of,
any premium, if any, and interest on, the debt securities of the series on the
dates payments are due.
Form, Exchange, and Transfer
We will issue the notes of each series only in fully registered form without
coupons and, unless we otherwise specify in the applicable prospectus
supplement, in denominations of $1,000 and any integral multiple thereof. The
indentures provide that we may issue notes of a series in temporary or
permanent global form and as book-entry securities that will be deposited with,
or on behalf of, The Depository Trust Company or another depository named by us
and identified in a prospectus supplement with respect to that series. See
"Legal Ownership of Securities" for a further description of the terms relating
to any book-entry securities.
At the option of the holder, subject to the terms of the indentures and the
limitations applicable to global securities described in the applicable
prospectus supplement, the holder of the notes of any series can exchange the
notes for other notes of the same series, in any authorized denomination and of
like tenor and aggregate principal amount.
Subject to the terms of the indentures and the limitations applicable to
global securities set forth in the applicable prospectus supplement, holders of
the notes may present the notes for exchange or for registration of transfer,
duly endorsed or with the form of transfer endorsed thereon duly executed if so
required by us or the security registrar, at the office of the security
registrar or at the office of any transfer agent designated by us for this
purpose. Unless otherwise provided in the notes that the holder presents for
transfer or exchange, we will make no service charge for any registration of
transfer or exchange, but we may require payment of any taxes or other
governmental charges.
We will name in the applicable prospectus supplement the security registrar,
and any transfer agent in addition to the security registrar, that we initially
designate for any notes. We may at any time designate additional transfer
agents or rescind the designation of any transfer agent or approve a change in
the office through which any transfer agent acts, except that we will be
required to maintain a transfer agent in each place of payment for the notes of
each series.
If we elect to redeem the notes of any series, we will not be required to:
. issue, register the transfer of, or exchange any notes of that series
during a period beginning at the opening of business 15 days before the
day of mailing of a notice of redemption of any notes that may be
selected for redemption and ending at the close of business on the day of
the mailing; or
. register the transfer of or exchange any notes so selected for
redemption, in whole or in part, except the unredeemed portion of any
notes we are redeeming in part.
25
<PAGE>
Information Concerning the Debenture Trustee
The debenture trustee, other than during the occurrence and continuance of
an event of default under an indenture, undertakes to perform only those duties
as are specifically set forth in the applicable indenture. Upon an event of
default under an indenture, the debenture trustee must use the same degree of
care as a prudent person would exercise or use in the conduct of his or her own
affairs. Subject to this provision, the debenture trustee is under no
obligation to exercise any of the powers given it by the indentures at the
request of any holder of notes unless it is offered reasonable security and
indemnity against the costs, expenses and liabilities that it might incur.
Payment and Paying Agents
Unless we otherwise indicate in the applicable prospectus supplement, we
will make payment of the interest on any notes on any interest payment date to
the person in whose name the notes, or one or more predecessor securities, are
registered at the close of business on the regular record date for the
interest.
We will pay principal of and any premium and interest on the notes of a
particular series at the office of the paying agents designated by us, except
that unless we otherwise indicate in the applicable prospectus supplement, will
we make interest payments by check which we will mail to the holder. Unless we
otherwise indicate in a prospectus supplement, we will designate the corporate
trust office of the debenture trustee in the City of New York as our sole
paying agent for payments with respect to notes of each series. We will name in
the applicable prospectus supplement any other paying agents that we initially
designate for the notes of a particular series. We will maintain a paying agent
in each place of payment for the notes of a particular series.
All money we pay to a paying agent or the debenture trustee for the payment
of the principal of or any premium or interest on any notes which remains
unclaimed at the end of two years after such principal, premium or interest has
become due and payable will be repaid to us, and the holder of the security
thereafter may look only to us for payment thereof.
Governing Law
The indentures and the notes will be governed by and construed in accordance
with the laws of the State of New York, except to the extent that the Trust
Indenture Act is applicable.
Subordination of Subordinated Notes
The subordinated notes will be unsecured and will be subordinate and junior
in priority of payment to certain of our other indebtedness to the extent
described in a prospectus supplement. The subordinated indenture does not limit
the amount of subordinated notes which we may issue. It also does not limit us
from issuing any other secured or unsecured debt.
26
<PAGE>
DESCRIPTION OF WARRANTS
The following description, together with the additional information we may
include in any applicable prospectus supplements, summarizes the material
terms and provisions of the warrants that we may offer under this prospectus
and the related warrant agreements and warrant certificates. While the terms
summarized below will apply generally to any warrants that we may offer, we
will describe the particular terms of any series of warrants in more detail in
the applicable prospectus supplement. If we indicate in the prospectus
supplement, the terms of any warrants offered under that prospectus supplement
may differ from the terms described below. Specific warrant agreements will
contain additional important terms and provisions and will be incorporated by
reference as an exhibit to the registration statement which includes this
prospectus.
General
We may issue warrants for the purchase of common stock, preferred stock
and/or debt securities in one or more series. We may issue warrants
independently or together with common stock, preferred stock and/or debt
securities, and the warrants may be attached to or separate from these
securities.
We will evidence each series of warrants by warrant certificates that we
will issue under a separate agreement. We will enter into the warrant
agreement with a warrant agent. Each warrant agent will be a bank that we
select which has its principal office in the United States and a combined
capital and surplus of at least $50,000,000. We will indicate the name and
address of the warrant agent in the applicable prospectus supplement relating
to a particular series of warrants.
We will describe in the applicable prospectus supplement the terms of the
series of warrants, including:
. the offering price and aggregate number of warrants offered;
. the currency for which the warrants may be purchased;
. if applicable, the designation and terms of the securities with which the
warrants are issued and the number of warrants issued with each such
security or each principal amount of such security;
. if applicable, the date on and after which the warrants and the related
securities will be separately transferable;
. in the case of warrants to purchase debt securities, the principal amount
of debt securities purchasable upon exercise of one warrant and the price
at, and currency in which, this principal amount of debt securities may
be purchased upon such exercise;
. in the case of warrants to purchase common stock or preferred stock, the
number of shares of common stock or preferred stock, as the case may be,
purchasable upon the exercise of one warrant and the price at which these
shares may be purchased upon such exercise;
. the effect of any merger, consolidation, sale or other disposition of our
business on the warrant agreement and the warrants;
. the terms of any rights to redeem or call the warrants;
. any provisions for changes to or adjustments in the exercise price or
number of securities issuable upon exercise of the warrants;
. the dates on which the right to exercise the warrants will commence and
expire;
. the manner in which the warrant agreement and warrants may be modified;
. federal income tax consequences of holding or exercising the warrants;
. the terms of the securities issuable upon exercise of the warrants; and
. any other specific terms, preferences, rights or limitations of or
restrictions on the warrants.
27
<PAGE>
Before exercising their warrants, holders of warrants will not have any of
the rights of holders of the securities purchasable upon such exercise,
including:
. in the case of warrants to purchase debt securities, the right to receive
payments of principal of, or premium, if any, or interest on, the debt
securities purchasable upon exercise or to enforce covenants in the
applicable indenture; or
. in the case of warrants to purchase common stock or preferred stock, the
right to receive dividends, if any, or, payments upon our liquidation,
dissolution or winding up or to exercise voting rights, if any.
Exercise of Warrants
Each warrant will entitle the holder to purchase the securities that we
specify in the applicable prospectus supplement at the exercise price that we
describe in the applicable prospectus supplement. Unless we otherwise specify
in the applicable prospectus supplement, holders of the warrants may exercise
the warrants at any time up to 5:00 P.M. Boston, Massachusetts time on the
expiration date that we set forth in the applicable prospectus supplement.
After the close of business on the expiration date, unexercised warrants will
become void.
Holders of the warrants may exercise the warrants by delivering the warrant
certificate representing the warrants to be exercised together with specified
information, and paying the required amount to the warrant agent in immediately
available funds, as provided in the applicable prospectus supplement. We will
set forth on the reverse side of the warrant certificate and in the applicable
prospectus supplement the information that the holder of the warrant will be
required to deliver to the warrant agent.
Upon receipt of the required payment and the warrant certificate properly
completed and duly executed at the corporate trust office of the warrant agent
or any other office indicated in the applicable prospectus supplement, we will
issue and deliver the securities purchasable upon such exercise. If fewer than
all of the warrants represented by the warrant certificate are exercised, then
we will issue a new warrant certificate for the remaining amount of warrants.
If we so indicate in the applicable prospectus supplement, holders of the
warrants may surrender securities as all or part of the exercise price for
warrants.
Enforceability of Rights By Holders of Warrants
Each warrant agent will act solely as our agent under the applicable warrant
agreement and will not assume any obligation or relationship of agency or trust
with any holder of any warrant. A single bank or trust company may act as
warrant agent for more than one issue of warrants. A warrant agent will have no
duty or responsibility in case of any default by us under the applicable
warrant agreement or warrant, including any duty or responsibility to initiate
any proceedings at law or otherwise, or to make any demand upon us. Any holder
of a warrant may, without the consent of the related warrant agent or the
holder of any other warrant, enforce by appropriate legal action its right to
exercise, and receive the securities purchasable upon exercise of, its
warrants.
28
<PAGE>
LEGAL OWNERSHIP OF SECURITIES
We can issue securities in registered form or in the form of one or more
global securities. We describe global securities in greater detail below. We
refer to those persons who have securities registered in their own names on the
books that we or any applicable trustee maintain for this purpose as the
"holders" of those securities. These persons are the legal holders of the
securities. We refer to those persons who, indirectly through others, own
beneficial interests in securities that are not registered in their own names,
as "indirect holders" of those securities. As we discuss below, indirect
holders are not legal holders, and investors in securities issued in book-entry
form or in street name will be indirect holders.
Book-Entry Holders
We may issue securities in book-entry form only, as we will specify in the
applicable prospectus supplement. This means securities may be represented by
one or more global securities registered in the name of a financial institution
that holds them as depositary on behalf of other financial institutions that
participate in the depositary's book-entry system. These participating
institutions, which are referred to as participants, in turn, hold beneficial
interests in the securities on behalf of themselves or their customers.
Only the person in whose name a security is registered is recognized as the
holder of that security. Securities issued in global form will be registered in
the name of the depositary or its participants. Consequently, for securities
issued in global form, we will recognize only the depositary as the holder of
the securities, and we will make all payments on the securities to the
depositary. The depositary passes along the payments it receives to its
participants, which in turn pass the payments along to their customers who are
the beneficial owners. The depositary and its participants do so under
agreements they have made with one another or with their customers; they are
not obligated to do so under the terms of the securities.
As a result, investors in a book-entry security will not own securities
directly. Instead, they will own beneficial interests in a global security,
through a bank, broker or other financial institution that participates in the
depositary's book-entry system or holds an interest through a participant. As
long as the securities are issued in global form, investors will be indirect
holders, and not holders, of the securities.
Street Name Holders
We may terminate a global security or issue securities in non-global form.
In these cases, investors may choose to hold their securities in their own
names or in "street name." Securities held by an investor in street name would
be registered in the name of a bank, broker or other financial institution that
the investor chooses, and the investor would hold only a beneficial interest in
those securities through an account he or she maintains at that institution.
For securities held in street name, we will recognize only the intermediary
banks, brokers and other financial institutions in whose names the securities
are registered as the holders of those securities, and we will make all
payments on those securities to them. These institutions pass along the
payments they receive to their customers who are the beneficial owners, but
only because they agree to do so in their customer agreements or because they
are legally required to do so. Investors who hold securities in street name
will be indirect holders, not holders, of those securities.
Legal Holders
Our obligations, as well as the obligations of any applicable trustee and of
any third parties employed by us or a trustee, run only to the legal holders of
the securities. We do not have obligations to investors who hold beneficial
interests in global securities, in street name or by any other indirect means.
This will be the case whether an investor chooses to be an indirect holder of a
security or has no choice because we are issuing the securities only in global
form.
29
<PAGE>
For example, once we make a payment or give a notice to the holder, we have
no further responsibility for the payment or notice even if that holder is
required, under agreements with depositary participants or customers or by law,
to pass it along to the indirect holders but does not do so. Similarly, we may
want to obtain the approval of the holders to amend an indenture, to relieve us
of the consequences of a default or of our obligation to comply with a
particular provision of the indenture or for other purposes. In such an event,
we would seek approval only from the holders, and not the indirect holders, of
the securities. Whether and how the holders contact the indirect holders is up
to the holders.
Special Considerations for Indirect Holders
If you hold securities through a bank, broker or other financial
institution, either in book-entry form or in street name, you should check with
your own institution to find out:
. how it handles securities payments and notices;
. whether it imposes fees or charges;
. how it would handle a request for the holders' consent, if ever required;
. whether and how you can instruct it to send you securities registered in
your own name so you can be a holder, if that is permitted in the future;
. how it would exercise rights under the securities if there were a default
or other event triggering the need for holders to act to protect their
interests; and
. if the securities are in book-entry form, how the depositary's rules and
procedures will affect these matters.
Global Securities
A global security is a security held by a depositary which represents one or
any other number of individual securities. Generally, all securities
represented by the same global securities will have the same terms.
Each security issued in book-entry form will be represented by a global
security that we deposit with and register in the name of a financial
institution or its nominee that we select. The financial institution that we
select for this purpose is called the depositary. Unless we specify otherwise
in the applicable prospectus supplement, The Depository Trust Company, New
York, New York, known as DTC, will be the depositary for all securities issued
in book-entry form.
A global security may not be transferred to or registered in the name of
anyone other than the depositary, its nominee or a successor depositary, unless
special termination situations arise. We describe those situations below under
"--Special Situations When a Global Security Will Be Terminated." As a result
of these arrangements, the depositary, or its nominee, will be the sole
registered owner and holder of all securities represented by a global security,
and investors will be permitted to own only beneficial interests in a global
security. Beneficial interests must be held by means of an account with a
broker, bank or other financial institution that in turn has an account with
the depositary or with another institution that does. Thus, an investor whose
security is represented by a global security will not be a holder of the
security, but only an indirect holder of a beneficial interest in the global
security.
If the prospectus supplement for a particular security indicates that the
security will be issued in global form only, then the security will be
represented by a global security at all times unless and until the global
security is terminated. If termination occurs, we may issue the securities
through another book-entry clearing system or decide that the securities may no
longer be held through any book-entry clearing system.
30
<PAGE>
Special Considerations for Global Securities
As an indirect holder, an investor's rights relating to a global security
will be governed by the account rules of the investor's financial institution
and of the depositary, as well as general laws relating to securities
transfers. We do not recognize an indirect holder as a holder of securities
and instead deal only with the depositary that holds the global security.
If securities are issued only in the form of a global security, an investor
should be aware of the following:
. An investor cannot cause the securities to be registered in his or her
name, and cannot obtain non-global certificates for his or her interest
in the securities, except in the special situations we describe below;
. An investor will be an indirect holder and must look to his or her own
bank or broker for payments on the securities and protection of his or
her legal rights relating to the securities, as we describe under "--
Legal Ownership of Securities" above;
. An investor may not be able to sell interests in the securities to some
insurance companies and to other institutions that are required by law to
own their securities in non-book-entry form;
. An investor may not be able to pledge his or her interest in a global
security in circumstances where certificates representing the securities
must be delivered to the lender or other beneficiary of the pledge in
order for the pledge to be effective;
. The depositary's policies, which may change from time to time, will
govern payments, transfers, exchanges and other matters relating to an
investor's interest in a global security. We and any applicable trustee
have no responsibility for any aspect of the depositary's actions or for
its records of ownership interests in a global security. We and the
trustee also do not supervise the depositary in any way;
. The depositary may, and we understand that DTC will, require that those
who purchase and sell interests in a global security within its book-
entry system use immediately available funds, and your broker or bank may
require you to do so as well; and
. Financial institutions that participate in the depositary's book-entry
system, and through which an investor holds its interest in a global
security, may also have their own policies affecting payments, notices
and other matters relating to the securities. There may be more than one
financial intermediary in the chain of ownership for an investor. We do
not monitor and are not responsible for the actions of any of those
intermediaries.
Special Situations When a Global Security will be Terminated
In a few special situations described below, the global security will
terminate and interests in it will be exchanged for physical certificates
representing those interests. After that exchange, the choice of whether to
hold securities directly or in street name will be up to the investor.
Investors must consult their own banks or brokers to find out how to have
their interests in securities transferred to their own name, so that they will
be direct holders. We have described the rights of holders and street name
investors above.
The global security will terminate when the following special situations
occur:
. if the depositary notifies us that it is unwilling, unable or no longer
qualified to continue as depositary for that global security and we do
not appoint another institution to act as depositary within 90 days;
. if we notify any applicable trustee that we wish to terminate that global
security; or
. if an event of default has occurred with regard to securities represented
by that global security and has not been cured or waived.
The prospectus supplement may also list additional situations for
terminating a global security that would apply only to the particular series
of securities covered by the prospectus supplement. When a global security
terminates, the depositary, and not we or any applicable trustee, is
responsible for deciding the names of the institutions that will be the
initial direct holders.
31
<PAGE>
PLAN OF DISTRIBUTION
We may sell the securities being offered hereby in one or more of the
following ways from time to time:
. through dealers or agents to the public or to investors;
. to underwriters for resale to the public or to investors;
. directly to investors; or
. through a combination of such methods.
We will set forth in a prospectus supplement the terms of the offering of
securities, including:
. the name or names of any agents, dealers or underwriters;
. the purchase price of the securities being offered and the proceeds we
will receive from the sale;
. any over-allotment options under which underwriters may purchase
additional securities from us;
. any agency fees or underwriting discounts and other items constituting
agents' or underwriters' compensation;
. any discounts or concessions allowed or reallowed or paid to dealers; and
. any securities exchanges on which such securities may be listed.
32
<PAGE>
LEGAL MATTERS
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., Boston, Massachusetts,
will provide us with an opinion as to the legal matters in connection with the
securities we are offering.
EXPERTS
The financial statements incorporated in this Prospectus by reference from
the Company's Annual Report on Form 10-K for the year ended December 31, 1999
have been audited by Deloitte & Touche LLP, independent auditors, as stated in
their report, which is incorporated herein by reference, and have been so
incorporated in reliance upon the report of such firm given upon their
authority as experts in accounting and auditing.
WHERE YOU CAN FIND MORE INFORMATION
We are a public company and file annual, quarterly and special reports,
proxy statements and other information with the Securities and Exchange
Commission. You may read and copy any document we file at the SEC's Public
Reference Room at 450 Fifth Street, N.W., Washington, D.C. 20549. You can
request copies of these documents by writing to the SEC and paying a fee for
the copying cost. Please call the SEC at 1-800-SEC-0330 for more information
about the operation of the public reference room. Our SEC filings are also
available to the public at the SEC's web site at "http://www.sec.gov." In
addition, our stock is listed for trading on the Nasdaq National Market. You
can read and copy reports and other information concerning us at the offices of
the National Association of Securities Dealers, Inc. located at 1735 K Street,
Washington, D.C. 20006.
This prospectus is only part of a Registration Statement on Form S-3 that we
have filed with the SEC under the Securities Act of 1933 and therefore omits
certain information contained in the Registration Statement. We have also filed
exhibits and schedules with the Registration Statement that are excluded from
this prospectus, and you should refer to the applicable exhibit or schedule for
a complete description of any statement referring to any contract or other
document. You may:
-- inspect a copy of the Registration Statement, including the exhibits and
schedules, without charge at the public reference room or,
-- obtain a copy from the SEC upon payment of the fees prescribed by the
SEC.
INCORPORATION OF DOCUMENTS BY REFERENCE
The SEC allows us to "incorporate by reference" the information we file with
it, which means that we can disclose important information to you by referring
you to those documents. The information incorporated by reference is considered
to be part of this prospectus and information we file later with the SEC will
automatically update and supersede this information. We incorporate by
reference the documents listed below and any future filings made with the SEC
under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of
1934. The documents we are incorporating by reference are:
Annual Report on Form 10-K for the year ended December 31, 1999, filed
on March 7, 2000; Quarterly Report on Form 10-Q for the quarter ended March
31, 2000, filed on May 12, 2000; Quarterly Report on Form 10-Q for the
quarter ended June 30, 2000, filed on August 9, 2000; Definitive Proxy
Statement, filed on April 25, 2000; Current Report on Form 8-K, filed on
January 28, 2000; Current Report on Form 8-K, filed on February 15, 2000;
Current Report on Form 8-K, filed on March 2, 2000; Current Report on Form
8-K, filed on April 17, 2000; Current Report on Form 8-K, filed on June 7,
2000; and
33
<PAGE>
The description of the common stock contained in our Registration
Statement on Form S-1 filed with the SEC on October 16, 1997, including any
amendments or reports filed for the purpose of updating such description.
You may request, orally or in writing, a copy of these documents, which
will be provided to you at no cost, by contacting:
Investor Relations CuraGen Corporation 555 Long Wharf Drive, 11th floor
New Haven, Connecticut 06511 Telephone: (203) 401-3330
34
<PAGE>
PART II. INFORMATION NOT REQUIRED IN PROSPECTUS
Item 14. Other Expenses of Issuance and Distribution
The following table sets forth the Company's estimates (other than the SEC
and Nasdaq registration fees) of the expenses in connection with the issuance
and distribution of the shares of common stock being registered. None of the
following expenses are being paid by the selling holders.
<TABLE>
<CAPTION>
Item Amount
---- --------
<S> <C>
SEC registration fee............................................... $132,000
Nasdaq listing fee................................................. 25,000
Legal fees and expenses............................................ 10,000
Accounting fees and expenses....................................... 150,000
Printing Fees...................................................... 20,000
Miscellaneous fees and expenses.................................... 6,000
--------
Total............................................................ $343,000
========
</TABLE>
Item 15. Indemnification of Directors and Officers.
The amendment and restatement of the Company's Certificate of Incorporation
(the "Restated Certificate") provides that the Company shall indemnify to the
fullest extent authorized by the Delaware General Corporation Law ("DGCL"),
each person who is involved in any litigation or other proceeding because such
person is or was a director or officer of the Company or is or was serving as
an officer or director of another entity at the request of the Company, against
all expense, loss or liability reasonably incurred or suffered in connection
therewith. The Restated Certificate provides that the right to indemnification
includes the right to be paid expenses incurred in defending any proceeding in
advance of its final disposition; provided, however, that such advance payment
will only be made upon delivery to the Company of an undertaking, by or on
behalf of the director or officer, to repay all amounts so advanced if it is
ultimately determined that such director is not entitled to indemnification. If
the Company does not pay a proper claim for indemnification in full within 60
days after a written claim for such indemnification is received by the Company,
the Restated Bylaws authorize the claimant to bring an action against the
Company and prescribe what constitutes a defense to such action.
Section 145 of the DGCL permits a corporation to indemnify any director or
officer of the corporation against expenses (including attorney's fees),
judgments, fines and amounts paid in settlement actually and reasonably
incurred in connection with any action, suit or proceeding brought by reason of
the fact that such person is or was a director or officer of the corporation,
if such person acted in good faith and in a manner that he or she reasonably
believed to be in, or not opposed to, the best interests of the corporation,
and, with respect to any criminal action or proceeding, if he or she had no
reason to believe his or her conduct was unlawful. In a derivative action,
(i.e., one brought by or on behalf of the corporation), indemnification may be
made only for expenses, actually and reasonably incurred by any director or
officer in connection with the defense or settlement of such an action or suit,
if such person acted in good faith and in a manner that he reasonably believed
to be in, or not opposed to, the best interests of the corporation, except that
no indemnification shall be made if such person shall have been adjudged to be
liable to the corporation, unless and only to the extent that the court in
which the action or suit was brought shall determine that the defendant is
fairly and reasonably entitled to indemnity for such expenses despite such
adjudication of liability.
Pursuant to Section 102(b)(7) of the DGCL, Article Tenth of the Restated
Certificate eliminates the liability of a director or the corporation or its
stockholders for monetary damages for such breach of fiduciary duty as a
director, except for liabilities arising (i) from any breach of the director's
duty of loyalty to the
II-1
<PAGE>
corporation or its stockholders, (ii) from acts or omissions not in good faith
or which involve intentional misconduct or a knowing violation of law, (iii)
under Section 174 of the DGCL, or (iv) from any transaction from which the
director derived an improper personal benefit. The Company has obtained primary
and excess insurance policies insuring the directors and officers of the
Company against certain liabilities that they may incur in their capacity as
directors and officers. Under such policies, the insurers, on behalf of the
Company, may also pay amounts for which the Company has granted indemnification
to the directors or officers.
Item 16. Exhibits
(a) Exhibits.
<TABLE>
<C> <S>
1.1*** The form of equity underwriting agreement will be filed as an exhibit
to a Current Report of the Registrant on Form 8-K and incorporated
herein by reference.
1.2*** The form of debt underwriting agreement will be filed as an exhibit to
a Current Report of the Registrant on Form 8-K and incorporated herein
by reference.
3.1* Amended and Restated Certificate of Incorporation of the Registrant,
as amended.
3.2* Amended and Restated By-Laws of the Registrant, as amended.
4.1 Form of senior indenture.
4.2 Form of subordinated indenture.
4.3** Specimen common stock certificate.
4.4*** The form of any senior note with respect to each particular series of
senior notes issued hereunder will be filed as an exhibit to a
Current Report of the Registrant on Form 8-K and incorporated herein
by reference.
4.5*** The form of any subordinated note with respect to each particular
series of subordinated notes issued hereunder will be filed as an
exhibit to a Current Report on the Registrant of Form 8-K and
incorporated hereby by reference.
4.6*** The form of any certificate of designation with respect to any
preferred stock issued hereunder and the related form of preferred
stock certificate will be filed as exhibits to a Current Report of
the Registrant on Form 8-K and incorporated herein by reference.
5.1 Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
regarding legality of securities being registered.
23.1 Consent of Deloitte & Touche LLP.
24.1 Power of Attorney (included on signature page).
25.1*** The Statement of Eligibility on Form T-1 under the Trust Indenture
Act of 1939, as amended, of the Trustee under the Senior Indenture
will be incorporated herein by reference from a subsequent filing in
accordance with Section 305(b)(2) of the Trust Indenture Act of 1939.
25.2*** The Statement of Eligibility on Form T-1 under the Trust Indenture
Act of 1939, as amended, of the Trustee under the Subordinated
Indenture will be incorporated herein by reference from a subsequent
filing in accordance with Section 305(b)(2) of the Trust Indenture
Act of 1939.
</TABLE>
--------
* Incorporated by reference to the Registrant's Registration Statement on
Form S-3/A filed on February 23, 2000.
** Incorporated by reference to Exhibit 4.2 to the Registrant's Registration
Statement on Form S-1/A filed on March 13, 1998 (File No. 333-38051).
*** To be filed by amendment or as an exhibit to a report pursuant to Section
13(a), 13(c) or 15(d) of the Exchange Act.
II-2
<PAGE>
Item 17. Undertakings
(a) The undersigned Registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made,
a post-effective amendment to this Registration Statement:
(i) To include any prospectus required by Section 10(a)(3) of the
Securities Act of 1933;
(ii) To reflect in the prospectus any facts or events arising after
the effective date of the registration statement (or the most recent
post-effective amendment thereof) which, individually or in the
aggregate, represent a fundamental change in the information set forth
in the registration statement. Notwithstanding the foregoing, any
increase or any decrease in volume of securities offered (if the total
dollar value of securities offered would not exceed that which was
registered) and any deviation from the low or high end of the estimated
maximum offering range may be reflected in the form of prospectus filed
with the Commission pursuant to Rule 424(b) if, in the aggregate, the
changes in volume and price represent no more than a 20% change in the
maximum aggregate offering price set forth in the "Calculation of
Registration Fee" table in the effective registration statement; and
(iii) To include any material information with respect to the plan
of distribution not previously disclosed in the registration statement
or any material change to such information in the registration
statement;
provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if
the registration statement is on Form S-3, Form S-8 or Form F-3, and the
information required to be included in a post-effective amendment by those
paragraphs is contained in periodic reports filed with or furnished to the
Commission by the Registrant pursuant to Section 13 or Section 15(d) of the
Securities Exchange Act of 1934 that are incorporated by reference in the
registration statement.
(2) That, for the purpose of determining any liability under the
Securities Act of 1933, each such post-effective amendment shall be deemed
to be a new registration statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed
to be the initial bona fide offering thereof.
(3) To remove from registration by means of a post-effective amendment
any of the securities being registered which remain unsold at the
termination of the offering.
(b) Insofar as indemnification for liabilities arising under the Securities
Act of 1933 may be permitted to directors, officers and controlling persons of
the Registrant, the Registrant has been advised that in the opinion of the
Securities and Exchange Commission such indemnification is against public
policy as expressed in the Act and is, therefore, unenforceable. In the event
that a claim for indemnification against such liabilities (other than the
payment by the Registrant of expenses incurred or paid by a director, officer
or controlling person of the Registrant in the successful defense of any
action, suit or proceeding) is asserted by such director, officer or
controlling person in connection with the securities being registered, the
Registrant will, unless in the opinion of its counsel the matter has been
settled by controlling precedent, submit to a court of appropriate jurisdiction
the question whether such indemnification by it is against public policy as
expressed in the Act and will be governed by the final adjudication of such
issue.
(c) The undersigned Registrant hereby undertakes that, for purposes of
determining any liability under the Securities Act of 1933, each filing of the
Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the
Securities Exchange Act of 1934 that is incorporated by reference in the
registration statement shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof.
(d) The undersigned registrant hereby undertakes to file an application for
the purpose of determining the eligibility of the trustee to act under
Subsection (a) of Section 310 of the Trust Indenture Act in accordance with the
rules and regulations prescribed by the Commission under Section 305(b)(2) of
the Trust Indenture Act.
II-3
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant
certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form S-3 and has duly caused this Registration
Statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in the City of New Haven and State of Connecticut on the 6th day of
October, 2000.
CuraGen Corporation
/s/ Jonathan M. Rothberg
By: _________________________________
Jonathan M. Rothberg
Chief Executive Officer, Chairman
of theBoard and President
POWER OF ATTORNEY
The registrant and each person whose signature appears below constitutes and
appoints Jonathan M. Rothberg, Ph.D. and David M. Wurzer, C.P.A. and each of
them singly, his, her or its true and lawful attorneys-in-fact and agents, with
full power of substitution and resubstitution, for him, her or it and in his,
her or its name, place and stead, in any and all capacities, to sign and file
(i) any and all amendments (including post-effective amendments) to this
Registration Statement, with all exhibits thereto, and other documents in
connection therewith, and (ii) a registration statement, and any and all
amendments thereto, relating to the offering covered hereby filed pursuant to
Rule 462(b) under the Securities Act of 1933, with the Securities and Exchange
Commission, granting unto said attorneys-in-fact and agents, and each of them,
full power and authority to do and perform each and every act and thing
requisite or necessary to be done in and about the premises, as fully to all
intents and purposes as he, she, or it might or could do in person, hereby
ratifying and confirming all that said attorneys-in-fact and agents or any of
them, or their or his substitute or substitutes, may lawfully do or cause to be
done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this
Registration Statement has been signed by the following persons in the
capacities and on the dates indicated.
<TABLE>
<CAPTION>
Signature Title Date
--------- ----- ----
<S> <C> <C>
/s/ Jonathan M. Rothberg Chief Executive Officer, October 6, 2000
______________________________________ Chairman of the Board of
Jonathan M. Rothberg Directors and President
(Principal Executive
Officer)
/s/ David M. Wurzer Executive Vice President, October 6, 2000
______________________________________ Treasurer and Chief
David M. Wurzer Financial Officer
(Principal Financial and
Accounting Officer)
/s/ Richard H. Booth Director October 6, 2000
______________________________________
Richard H. Booth
/s/ Vincent T. DeVita, Jr. Director October 6, 2000
______________________________________
Vincent T. DeVita, Jr.
/s/ Robert E. Patricelli Director October 6, 2000
______________________________________
Robert E. Patricelli
/s/ Randy Thurman Director October 6, 2000
______________________________________
Randy Thurman
</TABLE>
II-4
<PAGE>
EXHIBIT INDEX
<TABLE>
<CAPTION>
Exhibit
Number Exhibit
------- -------
<C> <S>
1.1*** The form of equity underwriting agreement will be filed as an exhibit
to a Current Report of the Registrant on Form 8-K and incorporated
herein by reference.
1.2*** The form of debt underwriting agreement will be filed as an exhibit to
a Current Report of the Registrant on Form 8-K and incorporated herein
by reference.
3.1* Amended and Restated Certificate of Incorporation of the Registrant,
as amended.
3.2* Amended and Restated By-Laws of the Registrant, as amended.
4.1 Form of senior indenture.
4.2 Form of subordinated indenture.
4.3** Specimen common stock certificate.
4.4*** The form of any senior note with respect to each particular series of
senior notes issued hereunder will be filed as an exhibit to a
Current Report of the Registrant on Form 8-K and incorporated herein
by reference.
4.5*** The form of any subordinated note with respect to each particular
series of subordinated notes issued hereunder will be filed as an
exhibit to a Current Report on the Registrant of Form 8-K and
incorporated hereby by reference.
4.6*** The form of any certificate of designation with respect to any
preferred stock issued hereunder and the related form of preferred
stock certificate will be filed as exhibits to a Current Report of
the Registrant on Form 8-K and incorporated herein by reference.
5.1 Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
regarding legality of securities being registered.
23.1 Consent of Deloitte & Touche LLP.
24.1 Power of Attorney (included on signature page).
25.1*** The Statement of Eligibility on Form T-1 under the Trust Indenture
Act of 1939, as amended, of the Trustee under the Senior Indenture
will be incorporated herein by reference from a subsequent filing in
accordance with Section 305(b)(2) of the Trust Indenture Act of 1939.
25.2*** The Statement of Eligibility on Form T-1 under the Trust Indenture
Act of 1939, as amended, of the Trustee under the Subordinated
Indenture will be incorporated herein by reference from a subsequent
filing in accordance with Section 305(b)(2) of the Trust Indenture
Act of 1939.
</TABLE>
--------
* Incorporated by reference to the Registrant's Registration Statement on
Form S-3/A filed on February 23, 2000.
** Incorporated by reference to Exhibit 4.2 to the Registrant's Registration
Statement on Form S-1/A filed on March 13, 1998 (File No. 333-38051).
*** To be filed by amendment or as an exhibit to a report pursuant to Section
13(a), 13(c) or 15(d) of the Exchange Act.
